Royalty Pharma plc · NASDAQ:RPRX

Royalty Pharma — UBS Global Healthcare Conference (May 2021)

18 slides from Royalty Pharma's conference presentation, May 24, 2021

  1. Slide 1: Royalty Pharma

    ROYALTY PHARMA

  2. Slide 2: UBS Global Healthcare Conference

    UBS Global Healthcare Conference Terrance Coyne, EVP, Chief Financial Officer Marshall Urist, EVP, Co-Head of Research & Investments May 24, 2021 2

  3. Slide 3: Forward Looking Statements & Non-GAAP Financial Information

    Forward Looking Statements & Non-GAAP Financial Information This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein do

  4. Slide 4: Q1 2021 – Executing against our strategy

    Q1 2021 – Executing against our strategy Strong double-digit top- and bottom-line growth(1) Robust deal flow with YTD transactions announced of $787m(2), including $582m upfront Exciting collaboration with MSCI on thematic indexes announced Raising full-year guidance for Adjusted Cash Receipts(3) (e

  5. Slide 5: Royalty Pharma overview

    Royalty Pharma overview Key Metrics Approved Products CF Franchise HIV Franchise Portfolio Metrics 45+ 21 ~15 Years Approved and Blockbuster Portfolio weighted development- $1bn+ therapies average royalty stage products in portfolio (1) duration Financial Metrics $1.8bn $1.5bn $1.7bn Adjusted Cash R

  6. Slide 6: Diversified across products, TAs and blue-chip marketers

    Diversified across products, TAs and blue-chip marketers 2020 Royalty Receipts By Product 2020 Royalty Receipts By Therapeutic Area 2020 Royalty Receipts By Marketer Other Other Other Cardiology Rare 14% 4% 15% 17% Hematology 4% Disease 6% 24% 24% 4% 3% 6% 6% Diabetes 4% 9% 5% (2) 6% 6% 15% Infectio

  7. Slide 7: Strong Adjusted Cash Flow conversion in Q1 2021

    Strong Adjusted Cash Flow conversion in Q1 2021 Q1 2021 Adjusted Cash Flow (Non-GAAP)(1) ($ in millions) 649 (126) 524 (42) (3) (63) $0.67/share(2) (7) 409 Royalty Receipts Non-Controlling Adjusted Cash Operating and R&D Funding Interest, net Other Adjusted Cash Flow Interest Receipts Professional C

  8. Slide 8: 2020 was a record year for biopharma royalty funding

    2020 was a record year for biopharma royalty funding Biopharma royalty market growth(1) Number of transactions Dollar value of transactions ($ in billions) 23 5.4 4.1 4.2 16 13 13 2.2 8 1.8 4 0.6 2015 2016 2017 2018 2019 2020 2015 2016 2017 2018 2019 2020 1. Internal estimates of historical biopharm

  9. Slide 9: Royalty Pharma has maintained ~60% overall share since 2012

    Royalty Pharma has maintained ~60% overall share since 2012 Estimated Royalty Market Size and Share by Transaction Value, 2012-May 2021(1) Royalty Pharma Other Royalty Buyers ~$2Bn ~$7Bn ~$6bn ~$13bn 18% 40% 66% 94% 82% 60% 34% 6% <$100m $100m - $250m $250m - $500m >$500m 1. Internal estimates of hi

  10. Slide 10: Royalty Pharma has specific competitive advantages

    Royalty Pharma has specific competitive advantages Other Buyers of Royalties Scale & Diversification Current portfolio of more than 45 products Comparable portfolios do not exist Publicly traded business with consistent cash flows Serial fund structures with Structure and the ability to leverage ent

  11. Slide 11: Cabometyx - leading TKI approved in multiple indications

    Cabometyx - leading TKI approved in multiple indications Sales evolution(1) ($ in millions) • Acquired GSK’s royalty in cabozantinib products Cabometyx/Cometriq +23% CAGR ▪ $342 million upfront, $50 million potential milestone payments 3,013(2) ▪ 3% royalty on worldwide net sales U.S. Non-U.S. • Cab

  12. Slide 12: Oxlumo - transformative rare disease therapy for PH1

    Oxlumo - transformative rare disease therapy for PH1 Primary Hyperoxaluria (PH) Type 1: • Acquired Dicerna’s royalty interest in Oxlumo (lumasiran) Patients in the U.S. / EU (2) ▪ $180 million upfront payment ▪ $60 million potential sales-based milestones ▪ Mid-high single digit royalty ~2,900-3,400

  13. Slide 13: Our clear strategic plan to continue growth

    Our clear strategic plan to continue growth Approved Late-Stage M&A therapies Development Select examples Select examples Select examples Acquire royalties on market- Acquire royalties on late-stage Acquire royalties through M&A leading approved therapies therapies with strong PoC data transactions

  14. Slide 14: Agnostic to therapeutic areas, modalities and drug class

    Agnostic to therapeutic areas, modalities and drug class Portfolio Agnostic to Therapeutic Areas and Unique Ability to Invest in Multiple Core Treatment Modalities Products in the Same Class Anti-TNFs Rare Disease Immunology (AbbVie) (Johnson & Johnson) (UCB) HIV Migraine 45+ (Eli Lilly) (Biohaven)

  15. Slide 15: Acquire approved and de-risked development-stage royalties

    Acquire approved and de-risked development-stage royalties Approved Status at Acquisition(1) Current Status(1) Since Acquisition Approved Products(2) • Predictable and de-risked Development-Stage Products Not Approved cash flows Total - $15.8bn $0.4bn, 2% $0.4bn, 3% (3) • Growth from increased penet

  16. Slide 16: Significant untapped opportunity for synthetic royalties

    Significant untapped opportunity for synthetic royalties Capital Raised by Biotech Companies, 2015-2019(1) • A synthetic royalty is created by the developer and/or marketer >$170bn of a therapy in exchange for funding • Multiple benefits to biotech partner: • Non-dilutive program-specific funding at

  17. Slide 17: A unique business at the center of biopharma innovation

    A unique business at the center of biopharma innovation Well positioned to leverage fast pace of biopharma innovation Agnostic to therapeutic categories and modalities Direct exposure to growth of transformative blockbuster therapies Long duration portfolio, highly diversified across products, thera

  18. Slide 18: Footnotes

    Footnotes 1) To aid in comparability, figures for each fiscal quarter in 2019 are presented on an unaudited pro forma basis, which adjusts certain cash flow line items as if Royalty Pharma’s Reorganization Transactions (as described in the Company’s final prospectus filed with the SEC on June 17, 20

Royalty Pharma — UBS Global Healthcare Conference (May 2021) on 6ix